3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
4
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pinealoma
1
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastric Cancer With Liver Metastases
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Interventions
Oxaliplatin
9
Capecitabine
9
Fluorouracil
7
pembrolizumab
6
Paclitaxel
6
Leucovorin
6
Cisplatin
5
zolbetuximab
4
trastuzumab deruxtecan
3
enzalutamide
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Gemcitabine
3
Docetaxel
3
fludarabine
2
darolutamide
2
Taxes
2
Ramucirumab
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Pemetrexed
2
Nivolumab
2
Irinotecan
2
Cyclophosphamide
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Immunotherapy
×
90 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled